AKT1 Inhibitors
1 drugsAbout AKT1
AKT1, also known as AKT, is a serine/threonine kinase involved in cell growth, proliferation, survival, and metabolism. It acts as a key node in multiple signaling pathways, regulating processes like glucose uptake and apoptosis.
AKT1 is a therapeutic target in oncology, with strong genetic evidence linking it to diseases like Cowden syndrome (score 0.80) and Proteus syndrome (score 0.66). Loss-of-function variants in AKT1 are protective against Proteus syndrome, suggesting inhibition may be beneficial.
There is one FDA-approved drug, TRUQAP, a small molecule targeting AKT1 for oncology indications. AstraZeneca is the sole company with an approved AKT1-targeting drug.
AKT1 Genetic Evidence Strong
AKT1 has strong genetic support with a max score of 0.80 across 13 diseases.
Strong genetic support suggests AKT1 inhibitors have an increased likelihood of clinical success.
💡 Why inhibition?
- • Loss-of-function variants reduce disease risk (OR < 1)
- • 50% directional consistency across 2 traits
- • Strong signal in genetic, familial or congenital disease, musculoskeletal or connective tissue disease, cancer or benign tumor pathways
Cross-Disease Effects
Trade-off: ModerateDirection of Effect
50% alignedEvidence Across Diseases
13 totalGWAS and other genetic studies link AKT1 to 13 diseases.
Inhibiting this target may be therapeutic
🔗 Colocalization Evidence 20 strong
max H4: 1.00eQTL/pQTL signals for AKT1 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top AKT1 Drugs
AstraZeneca is currently the only company with an approved AKT1-targeting drug.
The market's low competition presents an opportunity for other companies to enter the AKT1 inhibitor space.
AKT1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets AKT1, using small molecule modality.
The lack of diverse modalities indicates a whitespace opportunity for antibody or PROTAC development.
AKT1 Clinical Trials 44 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on AKT1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 21 | 8 | 0 | 13 | 100% |
| Phase 2 | 12 | 1 | 2 | 9 | 33% |
| Phase 3 | 11 | 0 | 0 | 11 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
3 Phase 3 trials testing approved AKT1 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting AKT1. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
AKT1 Drug Approval Timeline (2023 - 2023)
The first AKT1-targeting drug, TRUQAP, was approved in 2023.
The recent approval suggests a growing interest in AKT1 inhibition, but market saturation is not yet a concern.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 21 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on AKT1. A trial counts if an approved drug acting on AKT1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.